DK1244705T3 - Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf - Google Patents
Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser derafInfo
- Publication number
- DK1244705T3 DK1244705T3 DK00983938.2T DK00983938T DK1244705T3 DK 1244705 T3 DK1244705 T3 DK 1244705T3 DK 00983938 T DK00983938 T DK 00983938T DK 1244705 T3 DK1244705 T3 DK 1244705T3
- Authority
- DK
- Denmark
- Prior art keywords
- steap
- family
- human
- prostate cancer
- expressed
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000054725 human STEAP1 Human genes 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091077778 STEAP family Proteins 0.000 abstract 1
- 102000042326 STEAP family Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000005267 prostate cell Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/455,486 US6833438B1 (en) | 1999-06-01 | 1999-12-06 | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| PCT/US2000/033040 WO2001040276A2 (en) | 1999-12-06 | 2000-12-06 | Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1244705T3 true DK1244705T3 (da) | 2010-05-31 |
Family
ID=23809010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00983938.2T DK1244705T3 (da) | 1999-12-06 | 2000-12-06 | Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1642909A3 (enExample) |
| JP (3) | JP4827357B2 (enExample) |
| AT (1) | ATE456578T1 (enExample) |
| AU (2) | AU775366B2 (enExample) |
| CA (1) | CA2395053C (enExample) |
| CY (1) | CY1111034T1 (enExample) |
| DE (1) | DE60043784D1 (enExample) |
| DK (1) | DK1244705T3 (enExample) |
| ES (1) | ES2340249T3 (enExample) |
| IL (3) | IL150018A0 (enExample) |
| PT (1) | PT1244705E (enExample) |
| WO (1) | WO2001040276A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6329503B1 (en) | 1998-06-01 | 2001-12-11 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| US20060073150A1 (en) * | 2001-09-06 | 2006-04-06 | Mary Faris | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
| US7189565B2 (en) | 2001-03-23 | 2007-03-13 | Fahri Saatcioglu | Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| US7611892B2 (en) | 2000-03-24 | 2009-11-03 | President And Fellows Of Harvard College | Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| AU2001270118A1 (en) * | 2000-08-24 | 2002-03-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| WO2003087306A2 (en) * | 2002-04-05 | 2003-10-23 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| US7906620B2 (en) * | 2002-08-16 | 2011-03-15 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| JP5840351B2 (ja) | 2002-09-06 | 2016-01-06 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質 |
| EP1605893A4 (en) * | 2003-03-05 | 2008-08-13 | Innexus Biotechnology Inc | TRANS-MEMBRANE ANTIBODY-INDUCED APOPTOSIS INHIBITION |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| CA2557053A1 (en) * | 2004-02-19 | 2005-12-01 | Biomedisinsk Innovasjon As | Stamp2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| PT1742966E (pt) | 2004-04-22 | 2014-02-05 | Agensys Inc | Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1 |
| JP4191189B2 (ja) | 2005-12-08 | 2008-12-03 | 康生 梅津 | がん関連遺伝子活性化能を有するペプチド |
| JP5244103B2 (ja) * | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| MX2009003938A (es) | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| MY150531A (en) | 2007-07-16 | 2014-01-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| DK2657253T3 (en) | 2008-01-31 | 2017-10-09 | Genentech Inc | Anti-CD79b antibodies and immune conjugates and methods of use |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
| DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| WO2017083582A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| AU2017331361B2 (en) * | 2016-09-23 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| BR112019018767A2 (pt) | 2017-04-03 | 2020-05-05 | Hoffmann La Roche | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
| AU5243198A (en) * | 1996-10-30 | 1998-05-22 | Uab Research Foundation, The | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
| WO2000035937A1 (en) * | 1998-12-17 | 2000-06-22 | Human Genome Sciences, Inc. | 47 human secreted proteins |
| US6048970A (en) * | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
| US6329503B1 (en) * | 1998-06-01 | 2001-12-11 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US20020015950A1 (en) * | 1999-07-07 | 2002-02-07 | Karen Anne Jones | Atherosclerosis-associated genes |
| AU6906800A (en) * | 1999-08-17 | 2001-03-13 | Incyte Genomics, Inc. | Membrane associated proteins |
-
2000
- 2000-12-06 EP EP05014435A patent/EP1642909A3/en not_active Withdrawn
- 2000-12-06 EP EP00983938A patent/EP1244705B1/en not_active Expired - Lifetime
- 2000-12-06 WO PCT/US2000/033040 patent/WO2001040276A2/en not_active Ceased
- 2000-12-06 IL IL15001800A patent/IL150018A0/xx unknown
- 2000-12-06 JP JP2001541031A patent/JP4827357B2/ja not_active Expired - Lifetime
- 2000-12-06 AT AT00983938T patent/ATE456578T1/de active
- 2000-12-06 AU AU20629/01A patent/AU775366B2/en not_active Expired
- 2000-12-06 PT PT00983938T patent/PT1244705E/pt unknown
- 2000-12-06 ES ES00983938T patent/ES2340249T3/es not_active Expired - Lifetime
- 2000-12-06 DK DK00983938.2T patent/DK1244705T3/da active
- 2000-12-06 DE DE60043784T patent/DE60043784D1/de not_active Expired - Lifetime
- 2000-12-06 CA CA2395053A patent/CA2395053C/en not_active Expired - Lifetime
-
2002
- 2002-06-04 IL IL150018A patent/IL150018A/en active IP Right Grant
-
2004
- 2004-10-29 AU AU2004224964A patent/AU2004224964B2/en not_active Expired
-
2005
- 2005-12-19 JP JP2005365540A patent/JP2006204290A/ja not_active Withdrawn
-
2009
- 2009-06-10 IL IL199275A patent/IL199275A0/en active IP Right Grant
-
2010
- 2010-04-26 CY CY20101100373T patent/CY1111034T1/el unknown
- 2010-09-22 JP JP2010212334A patent/JP2011062201A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE60043784D1 (de) | 2010-03-18 |
| EP1244705A2 (en) | 2002-10-02 |
| CA2395053A1 (en) | 2001-06-07 |
| IL150018A0 (en) | 2002-12-01 |
| IL150018A (en) | 2011-04-28 |
| CA2395053C (en) | 2012-05-29 |
| EP1642909A2 (en) | 2006-04-05 |
| WO2001040276A2 (en) | 2001-06-07 |
| AU775366B2 (en) | 2004-07-29 |
| AU2004224964B2 (en) | 2008-10-02 |
| ES2340249T3 (es) | 2010-06-01 |
| CY1111034T1 (el) | 2015-08-05 |
| JP2006204290A (ja) | 2006-08-10 |
| EP1244705B1 (en) | 2010-01-27 |
| IL199275A0 (en) | 2011-07-31 |
| JP4827357B2 (ja) | 2011-11-30 |
| ATE456578T1 (de) | 2010-02-15 |
| EP1642909A3 (en) | 2006-04-12 |
| AU2062901A (en) | 2001-06-12 |
| JP2011062201A (ja) | 2011-03-31 |
| JP2003517306A (ja) | 2003-05-27 |
| AU2004224964A1 (en) | 2004-11-25 |
| WO2001040276A3 (en) | 2002-01-10 |
| PT1244705E (pt) | 2010-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1244705T3 (da) | Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf | |
| DE69941187D1 (de) | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen | |
| BR0108711A (pt) | Expressão heteróloga de proteìnas de neisseria | |
| ATE485371T1 (de) | Varianten des menschlichen koagulationsfaktors vii | |
| RU2002124123A (ru) | Модифицированный фактор viii | |
| DE69926647D1 (de) | Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| FR2649982B1 (fr) | Membrane biologique artificielle | |
| TR200100074T2 (tr) | Nevrotrofik büyüme faktörü | |
| CY1113218T1 (el) | Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας | |
| BR0213565A (pt) | Anticorpo de anti-tnf alfa modificado | |
| DK0749317T3 (da) | Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| ES2060803T3 (es) | Soporte biologico para cultivos celulares constituido por proteinas plasmaticas coaguladas por trombina, su utilizacion para el cultivo de los queratinocitos, su recuperacion y su transporte con fines de utilizacion terapeutica. | |
| DE69535719D1 (de) | Fas-antigenbindender ligand | |
| NO971341L (no) | Promoter for reseptor tyrosinkinase TIE | |
| CY1111431T1 (el) | Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων | |
| DE60226896D1 (de) | Herstellung von f(ab')2 fragmenten in saügetierzelle | |
| DE69837935D1 (de) | Nukleotid- und proteinsequenz von mammastatin und anwendungsmethoden | |
| ATE432292T1 (de) | Antitumorantikörper, proteine und deren verwendung | |
| BR0113623A (pt) | Proteìnas sintéticas de estìmulo da eritropoiese | |
| KONDO et al. | Study on coacervation of the repeat pentapeptide model of tropoelastin: effect of cations | |
| DE602004031886D1 (de) | Auf öligen substanzen basierte körperreinigungzubereitung | |
| DE69907727D1 (de) | Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen | |
| IL150045A0 (en) | Compositions and methods for detecting stress-inducible proteins |